Abstract
The aim of this study was to review the literature on quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis, and to identify the specific aspects of quality of life that were studied and reported in this population. We also set out to report predictors of quality of life. Published research reports were included if they described quality of life in this population and met methodological quality according to a list of predefined criteria. Eight studies (7 in NF1, 1 in NF2, 0 in schwannomatosis), conducted between 2001 and 2013, met inclusion criteria. The methodological quality of the eight studies was mostly high according to ratings by predefined criteria. Most studies reported that patients with NF experience decreased quality of life when compared to the general population. Visibility and disease severity were strong predictors of skin-specific quality of life in NF1 patients. However, the majority of findings regarding predictors of quality of life were weak or inconclusive. Given the decreased quality of life in NF patients, it is important to examine more comprehensively the psychosocial factors in this population, especially in patients with NF2 and schwannomatosis. Mind body interventions that address these domains may provide comprehensive and efficacious long term treatment.
Similar content being viewed by others
Explore related subjects
Discover the latest articles and news from researchers in related subjects, suggested using machine learning.References
Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 152A:327–332
Lu-Emerson C, Plotkin SR (2009) The neurofibromatoses. Part 1: NF1. Rev Neurol Dis 6:E47–E53
Lu-Emerson C, Plotkin SR (2009) The neurofibromatoses. Part 2: NF2 and schwannomatosis. Rev Neurol Dis 6:E81–E86
Antinheimo J, Sankila R, Carpen O, Pukkala E, Sainio M, Jaaskelainen J (2000) Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology 54:71–76
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097
Kuijpers T, van der Windt DA, van der Heijden GJ, Bouter LM (2004) Systematic review of prognostic cohort studies on shoulder disorders. Pain 109:420–431
Scholten-Peeters GG, Verhagen AP, Bekkering GE, van der Windt DA, Barnsley L, Oostendorp RA, Hendriks EJ (2003) Prognostic factors of whiplash-associated disorders: a systematic review of prospective cohort studies. Pain 104:303–322
Ariens GA, van Mechelen W, Bongers PM, Bouter LM, van der Wal G (2000) Physical risk factors for neck pain. Scand J Work Environ Health 26:7–19
Wolkenstein P, Zeller J, Revuz J, Ecosse E, Leplege A (2001) Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 cases. Arch Dermatol 137:1421–1425
Granstrom S, Langenbruch A, Augustin M, Mautner VF (2012) Psychological burden in adult neurofibromatosis type 1 patients: impact of disease visibility on body image. Dermatology 224:160–167
Cosyns M, Mortier G, Janssens S, Van BJ (2012) Voice-related quality of life in adults with neurofibromatosis type 1. J Voice 26:e57–e62
Langenbruch AK, Augustin M, Granstrom S, Kluwe L, Mautner VF (2011) Clinical and healthcare status of patients with neurofibromatosis type 1. Br J Dermatol 165:225–227
Neary WJ, Hillier VF, Flute T, Stephens SD, Ramsden RT, Evans DG (2010) The relationship between patients’ perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36. Clin Otolaryngol 35:291–299
Kodra Y, Giustini S, Divona L, Porciello R, Calviei S, Wolkenstein P, Taruscio D (2009) Health-related quality of life in patients with neurofibromatosis type 1. Dermatology 218:215–220
Page PZ, Page GP, Ecosse E, Korf BR, Leplege A, Wolkenstein P (2006) Impact of neurofibromatosis 1 on quality of life: a cross-sectional study of 176 American cases. Am J Med Genet A 140A:1893–1898
Nutakki K, Hingtgen CM, Monahan P, Varni JW, Swigonski NL (2013) Development of the adult PedsQL neurofibromatosis type 1 module: initial feasibility, reliability and validity. Health Qual Life Outcomes 11:21
Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483
Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ (1997) Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 133:1433–1440
Samuelsson B, Riccardi VM (1989) Neurofibromatosis in Gothenburg, Sweden. III. Psychiatric and social aspects. Neurofibromatosis 2:84–106
Bull AA, Meyerowitz BE, Hart S, Mosconi P, Apolone G, Liberati A (1999) Quality of life in women with recurrent breast cancer. Breast Cancer Res Treat 54:47–57
Downe-Wamboldt B, Butler L, Coulter L (2006) The relationship between meaning of illness, social support, coping strategies, and quality of life for lung cancer patients and their family members. Cancer Nurs 29:111–119
Carslon LE, Bultz BD (2004) Efficacy and medical cost offset of psychosocial interventions in cancer care: making the case of economic analyses. Psycho-oncology 13:347–837
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Vranceanu, AM., Merker, V.L., Park, E. et al. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. J Neurooncol 114, 257–262 (2013). https://doi.org/10.1007/s11060-013-1195-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-013-1195-2